| Symbol | Name | Last Close | Mkt Cap | DailyStocks' Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
|
Vote Now! Wednesday’s Close |
|---|---|---|---|---|---|
| SNY | Sanofi | $43.75 | $109.14B | Downtrend |
Stocks making the biggest move premarket: KMB, HAL, HAS, PII, INTC & more
https://www.cnbc.com/2018/10/22/stocks-making-the-biggest-move-premarket-kmb-hal-has-pii-intc--more.html
Oct 22, 2018 - Names on the move ahead of the open.
3
FDA OKs Regeneron and Sanofi's Dupixent for asthma
https://seekingalpha.com/news/3399067-fda-oks-regeneron-sanofis-dupixent-asthma?source=feed_news_all
Oct 20, 2018 - The FDA approves Regeneron Pharmaceuticals (NASDAQ:REGN) and development partner Sanofi's (NYSE:SNY) DUPIXENT (dupilumab) as add-on maintenance therapy in patients with moderate-to-severe asthma aged
0
10 'Safer' Dividend Healthcare WallStars Gain 12-23% Per Broker October Targets And Dividends
https://seekingalpha.com/article/4211834-10-safer-dividend-healthcare-wallstars-gain-12minus-23-percent-per-broker-october-targets?source=feed_all_articles
Oct 16, 2018 - October's top net gain safer Healthcare WallStar is AbbVie. Its projected 23% net gain was 2.3% better than Sanofi's, and 3.4% more than Grifol's result per analyst targets of 10/12/18.WallStars all s
1
Aimmune teams up with Regeneron and Sanofi in mid-stage peanut allergy study; shares up 1%
https://seekingalpha.com/news/3397330-aimmune-teams-regeneron-sanofi-mid-stage-peanut-allergy-study-shares-1-percent?source=feed_news_all
Oct 15, 2018 - Aimmune Therapeutics (AIMT +1.3%) is up on light volume on the heels of the initiation of a Phase 2 clinical trial evaluating AR101 with adjunctive DUPIXENT (dupilumab) in peanut-allergy patients.The
0
Healthcare 16-24% Target Net Gains Pace WallStars For October
https://seekingalpha.com/article/4211623-healthcare-16minus-24-percent-target-net-gains-pace-wallstars-october?source=feed_all_articles
Oct 15, 2018 - Big pharma drug makers and biotech continued to top the healthcare sector by broker targets. WallStars are distinguished by positive broker target price upsides.The Healthcare sector is comprised of 1
0
Sanofi eyeing large campus in Cambridge, MA
https://seekingalpha.com/news/3397251-sanofi-eyeing-large-campus-cambridge-ma?source=feed_news_all
Oct 15, 2018 - The Boston Globe reports that Sanofi's (NYSE:SNY) U.S. unit is planning a major expansion in East Cambridge, MA that may be as large as 400K square feet, enough to house 2K employees. The former rail
0
Merrimack (MACK) Focuses on Early Stage Pipeline and Cost Cuts
http://www.zacks.com/stock/news/327579/merrimack-mack-focuses-on-early-stage-pipeline-and-cost-cuts?cid=CS-ZC-FT-327579
Oct 11, 2018 - Merrimack (MACK) focuses on the development of its two early-stage pipeline candidates, MM-121 and MM-310. The candidates have been progressing well and are imperative to the company's growth.
0
Altimmune Declines Too Much
https://seekingalpha.com/article/4210760-altimmune-declines-much?source=feed_sector_healthcare
Oct 09, 2018 - Altimmune, Inc. is a clinical stage immunotherapeutics company developing robust and durable immune responses intended for the prevention and treatment of several illnesses.The market is too pessimist
0
Lexicon Likely Looking At Even More Competition In Type 1 Diabetes
https://seekingalpha.com/article/4210037-lexicon-likely-looking-even-competition-type-1-diabetes?source=feed_tag_editors_picks
Oct 05, 2018 - Data from Phase III trials of Lilly/Boehringer's Jardiance in Type 1 diabetes supports submission and commercialization, bringing another competitor into the market.Lexicon's sotagliflozin is not out
0
Biotech Stock Roundup: ALXN on Acquisition Spree, FDA Nod for REGN, AMGN Drugs
http://www.zacks.com/stock/news/326050/biotech-stock-roundup-alxn-on-acquisition-spree-fda-nod-for-regn-amgn-drugs?cid=CS-ZC-FT-326050
Oct 03, 2018 - The biotech sector grabs headlines this week with FDA approvals plus licensing and acquisition pacts.
0
Page 1>
Related Companies
| Name | Exchange | Price | Mkt Cap | |
| LLY | Eli Lilly and Company | NYSE | $105.71 | $113.53B |
| NVO | Novo Nordisk A/S | NYSE | $47.64 | $114.84B |
| BMY | Bristol-Myers Squibb Company | NYSE | $61.3 | $100.03B |
| ABT | Abbott Laboratories | NYSE | $67.67 | $118.71B |
| GSK | GlaxoSmithKline PLC | NYSE | $39.21 | $97.25B |